Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implantable contraception.

P D Darney1

  • 1Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco General Hospital, Center for Reproductive Health Research and Policy, University of California, San Francisco 94110, USA.

The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|March 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing maternal mortality due to elective abortion: Potential impact of misoprostol in low-resource settings.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2007
Same author

Contraception-associated menstrual problems: etiology and management.

Dialogues in contraception·2002
Same author

Practice guidelines for OC selection: update.

Dialogues in contraception·2002
Same author

Implant contraception.

Seminars in reproductive medicine·2001
Same author

Misoprostol: a boon to safe motherhood...or not?

Lancet (London, England)·2001
Same author

Time to pardon the IUD?

The New England journal of medicine·2001
Same journal

Dissociation of gonadal and adrenal androgens one year after etonogestrel implant insertion.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

A titrated low-dose misoprostol protocol for second-trimester abortion (13-26 weeks) in women with one prior cesarean and preterm premature rupture of membranes: a clinical practice report.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Factors associated with unplanned pregnancy among pregnant female adolescents in the Southeast region of Brazil: a cross-sectional study.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Contraceptive effectiveness of a digital contraceptive with a wearable device vs an oral thermometer.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Fertile-window misclassification in period-tracking applications and associated pregnancy risk: a large observational analysis.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Measurement of pain during first trimester medical abortion: an exploratory qualitative study.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
See all related articles

Progestogen-only contraceptive implants, like the new Implanon, offer effective, long-term birth control with fewer side effects than other methods. Implanon provides easy insertion and removal, making it a convenient contraceptive option.

Area of Science:

  • Reproductive Health
  • Contraception
  • Pharmacology

Background:

  • Progestogen-only contraceptive implants offer long-acting reversible contraception.
  • Previous formulations like Norplant have faced challenges with insertion and removal.
  • Implanon represents a new generation of single-rod etonogestrel-releasing implants.

Purpose of the Study:

  • To review the advantages and disadvantages of progestogen-only contraceptive implants.
  • To evaluate the development and characteristics of Implanon.
  • To compare Implanon with existing contraceptive methods.

Main Methods:

  • Review of existing literature on progestogen-only contraceptive implants.
  • Analysis of data regarding Implanon's efficacy, safety, and user acceptability.

Related Experiment Videos

  • Comparison of Implanon's performance with oral contraceptives, depot injections, and intrauterine devices.

    • Main Results:

    • Implants provide steady serum progestogen levels for 1-5 years, avoiding oral contraceptive peaks/troughs and depot injection ovarian suppression.
    • Implanon demonstrates ease of insertion/removal with minimal complications and pain.
    • The primary discontinuation reason is altered bleeding patterns, often managed with counseling; ectopic pregnancy and follicular hypertrophy rates are low.
    • Implanon shows an extremely high efficacy (Pearl Index of 0) with a new polymer and less androgenic progestogen.

    Conclusions:

    • Progestogen-only implants, particularly Implanon, are effective, safe, economical, and convenient contraceptive alternatives.
    • Implanon's design facilitates easier insertion/removal and potentially reduces androgenic side effects.
    • Improved counseling can mitigate bleeding pattern changes, enhancing user tolerance and overall acceptability.